I'm not sure if you're being ironic, but did you read Woodcock's comments? See the top article in headlines for SRPT.
Most institutions won't or can't buy pink sheet stocks. That's why uplisting is so important.
CCXI has an explanation. It's in some of their presentations. Something about too much drug triggers some adverse factor. Sounds fishy to me.
I may be wrong, but I believe LBIO's results are for monotherapy only, and they are planning studies with their drug combined with other drugs. Also, in the first quarter, Baker Brothers, Fidelity, Franklin, and Orbimed bought in. Those outfits seem to know their stuff.
The highest acceptable p value in a trial is .05. This means that the chance of the positive result being due to coincidence is 1 out of 20. The lower the p value, the more confident you can be that the positive result was actually due to the effects of the drug. Some trials have a p value of .001, meaning that the chance of the positive result being due to coincidence was 1 out of 1000.
I know a lot of people who lost fig trees over this past winter (in the northeast) because they didn't cover them. When my old fig trees got too big to cover, I at least covered the bottoms with mulch and a tarpaulin to protect the roots from the cold, and never lost any trees.
After the phase 2 trial, the company said that this drug will be tested for so many different conditions that they just don't have the resources to do it. I agree they made a bad deal though .Bayer will cook the books and cheat us.
I would think the deal CELG signed with Astra Zeneca would dampen BMY's interest in CELG ( if they had any interest).